BioSpace News Archive

The global Chronic Rhinosinusitis Market was valued at USD 2132.5 million in 2019 and is expected to reach USD 3508.0 million by 2027, at a CAGR of 7.4%, According to the current analysis of Emergen Research.

The global Point-Of-Care Testing (POCT) market size reached USD 39.80 Billion in 2021 and is expected to register a revenue CAGR of 10.9% during the forecast period, according to latest analysis by Emergen Research.

The global gene editing Market is projected to reach USD 15.79 billion by 2027, according to a recent report by Emergen Research. The market is expected to grow at a CAGR of 17.2% over the forecast period (2020-2027).

InnerScope Hearing Technologies Inc. is pleased to announce that the FDA has released the “Final Rule” for creating a new category of Over-the-Counter hearing aids for perceived mild to moderate hearing losses to be sold directly to consumers in retail stores, pharmacies and online without a medical exam or being fitted by a hearing healthcare professional.

VySpine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the FDA for its VyPlate Anterior Cervical Plate System.

Abivax SA, a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces a transition in the governance of its Board of Directors.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, announced their agreement to develop a companion diagnostic for use with Kronos Bio’s investigational therapy, entospletinib.

Personalis, Inc. announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan.

Aridis Pharmaceuticals, Inc. today reported financial and corporate results for its second quarter ended June 30, 2022.

Ambrx Biopharma Inc. today announced the appointment of Kate Hermans as interim Chief Executive Officer, replacing Feng Tian, Ph.D., effective immediately.